Biostage's new patent expands treatment into lungs
Courtesy | Biostage
Biostage President Hong Yu
Holliston biotechnology company Biostage Inc. has secured a patent to allow the company known for its esophageal cancer treatment research to pursue treatments for lung cancer.
The patent extends the company’s intellectual property to cover regeneration and repair of the bronchus due to cancer, injury, or birth defects, the company announced Monday.
This is an expansion of the company’s technology used in the esophagus in a study to treat esophageal cancer. The company received the patent after it used a cell-seeded scaffold, called the Biostage Bronchial Implant, for regeneration in and repair of a bronchus (the airway that connects the trachea to the lungs) that was surgically removed from a pig, according to a release.
This new patent gives Biostage protection needed to develop a business in treating lung cancer via the regeneration and repair of the bronchus, according to the company.
The news comes as Biostage recently reported net losses for 2021 of approximately $8 million, and that the company had enough cash to fund operations into the third quarter of this year.
WBJ Web Partners
Most Recent
Most Recent
0 Comments